Molecular Medicine Tumor Board: Whole-Genome Sequencing to Inform on Personalized Medicine for a Man with Advanced Prostate Cancer

This molecular tumor board is a rare example of having complete whole-genome sequencing data from the germline and tumor in a living patient facing aggressive prostate cancer in real-time. We provide a case report of how our multidisciplinary team of medical oncologists, pathologists, cancer biologists, and bioinformatics specialists thinks through the complexities of this big data and interprets it in the context of his care, and helps to explain the patient's extraordinary response to radiation and hormonal therapy over many years.

SPOP mutated prostate cancer represents a particularly hormone-sensitive variant of prostate cancer and this case illustrates how integrated genomics and precision oncology can inform on the different subsets of prostate cancer and outcomes. This patient has now made all of his genetic data available to the public in an act of great generosity to spur further research and treatments.

Written by: Andrew J. Armstrong, MD, ScM, FACP, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers, Divisions of Medical Oncology and Urology, Duke University

Read the Abstract

Login